<DOC>
	<DOCNO>NCT01177579</DOCNO>
	<brief_summary>Copper essential nutrient human cofactor enzymes participate critical body function . Insufficient copper lead hematological neurological abnormality may irreversible left untreated . Copper deficiency believe rare U.S. population typical dietary intake usually sufficient meet requirement . More recent evidence suggest specific population may susceptible copper deficiency case copper absorption gut impair follow gastric surgery individual high intake zinc . Preliminary study u others identify significant level moderate severe symptomatic copper deficiency patient undergone weight loss ( bariatric ) gastric bypass surgery . Copper deficiency human difficult recognize treat current diagnostic tool rely measure plasma concentration copper ceruloplasmin , neither sensitive specific copper deficiency , early warning blood marker ( biomarkers ) identify . Recent development indicate copper chaperone molecules cuproenzymes cytochrome C oxidase superoxide dismutase may sensitive change copper status , little work do human . The study outline aimed assess copper status use biomarkers gastric bypass surgery patient risk symptomatic copper deficiency . In addition , patient identify deficient supplement copper treatment evaluate use biomarker concentration . The findings study provide insight effectiveness novel biomarkers identify risk guide appropriate treatment prevent serious permanent morbidity due copper deficiency .</brief_summary>
	<brief_title>Human Biomarkers Assessing Copper Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Copper</mesh_term>
	<criteria>CuD subject In order enrol CuD Arm , subject RYGB surgery recruit screen eligibility ( inclusion exclusion criterion ) . Subjects whose plasma copper concentration deficient range ( le 80 μg/dL woman le 70 µg/dL men , and/or ceruloplasmin activity 62 units/L1 ) follow 4 week supplementation RDA copper eligible . Such supplementation routine standard care patient undergo RYGB surgery . This process aim exclude patient marginally copper deficient need sustain copper therapy . Subjects notify copper status study physician . They contact study team , willingness participate study determine . Inclusion criterion : 1 ) Patient history RYGB weight loss surgery ; 2 ) subject plasma copper level le 80 μg/dL woman andl less 70 µg/dL men , and/or ceruloplasmin activity 62 units/L1 ; 3 ) subject least 18 65 year age ; 4 ) subject sign informed consent . Exclusion criterion : 1 ) subject exhibit severe neurologic sign symptom ( e.g . severe paresthesia , severe gait disturbance , severe weakness require intravenous copper supplementation ; 2 ) subject pregnant ; 3 ) subject history surgical revision conversion bariatric procedure ; 4 ) subject history hospitalization acute illness previous 3 month ; 5 ) subject current active malignant neoplasm ; history malignancy localize basal cell cancer skin previous 5 year ; 6 ) subject current history type 1 type 2 diabetes mellitus . CuN subject In order enrol CuN control arm , subject RYGB surgery recruit screen eligibility ( inclusion exclusion criterion ) . Subjects plasma copper concentration normal range ( 80 155 μg/dL woman 70 140 µg/dL men , and/or ceruloplasmin activity 62 units/L1 ) . Subjects also eligible match stage weight management ( either active weight loss weight stable ) gender CuD subject . Subjects notify copper status eligibility willingness participate study determine . Inclusion criterion : 1 ) Patient history RYGB weight loss surgery ; 2 ) subject plasma copper level 80 155 μg/dL woman 70 140 µg/dL men , and/or ceruloplasmin activity 62 units/L1 ; 3 ) subject match stage weight management gender CuD subject , 4 ) subject least 18 65 year age ; 5 ) subject sign informed consent . Exclusion criterion : 1 ) subject pregnant ; 2 ) subject history surgical revision conversion bariatric procedure ; 3 ) subject history hospitalization acute illness previous 3 month ; 4 ) subject current active malignant neoplasm ; history malignancy localize basal cell cancer skin previous 5 year ; 5 ) subject current history type 1 type 2 diabetes mellitus . NW Control Arm For normalweight control arm ( NW Control ) , subject bariatric surgery normal weight recruit . Inclusion criterion : 1 ) Subject plasma copper level 80 155 μg/dL woman 70 140 µg/dL men , and/or ceruloplasmin activity 62 units/L1 ; 2 ) subject normal weight , BMI 20 30 kg/m2 , 3 ) subject least 18 65 year age ; 4 ) subject sign informed consent . Exclusion criterion : 1 ) subject pregnant ; 2 ) subject history abdominal surgery history gastrointestinal disease ; 3 ) subject history hospitalization acute illness previous 3 month ; 4 ) subject current active malignant neoplasm ; history malignancy localize basal cell cancer skin previous 5 year ; 5 ) subject current history type 1 type 2 diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Bariatric surgery , copper deficiency , biomarkers</keyword>
</DOC>